Choose a language and wait for the translated text.
The medicine, which uses the same semaglutide active ingredient as Ozempic, will launch on July 27 and is registered by the South African Health Products Regulatory Authority (SAHPRA) as the country's only authorised semaglutide copy, the Danish drugmaker said in a statement late on Thursday.
Novo Nordisk to launch lower-cost Ozempic copy in South Africa | PharmaVoice
